ABT-888 increases tumor growth delay in a NCI-H460 xenograft model. ABT-888 enhances the antitumor activity of temozolomide in the B16F10 and 9L xenograft models due to PARP inhibition. ABT-888 exhibits good antitumor efficacy in MX-1 xenograft model in combination with other cytotoxic agents. Combination with radiation, ABT-888 decreases the tumor vessel formation. ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models.
Biotool LLC
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!